Becton, Dickinson and Company (NYSE:BDX) Stock Has Average Price Target of $185.07

Shares of Becton, Dickinson and Company (NYSE:BDX) have received a consensus rating of “Hold” from the seventeen ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $185.07.

Several analysts have issued reports on BDX shares. Bank of America boosted their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Piper Sandler increased their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Finally, Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,906 shares of company stock worth $1,265,855 over the last quarter. 0.40% of the stock is currently owned by company insiders.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors have recently modified their holdings of BDX. BlackRock Inc. bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at $3,721,533,000. State Street Corp raised its position in Becton, Dickinson and Company by 8.5% in the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after purchasing an additional 1,177,256 shares during the period. First Eagle Investment Management LLC lifted its stake in Becton, Dickinson and Company by 15.8% in the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares during the last quarter. Bank of America Corp DE bought a new stake in Becton, Dickinson and Company in the second quarter worth $474,993,000. Finally, Legal & General Group Plc boosted its position in Becton, Dickinson and Company by 1.5% during the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock valued at $318,050,000 after buying an additional 30,766 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.5%

Shares of BDX stock opened at $190.82 on Tuesday. The company has a 50 day moving average of $184.26 and a 200-day moving average of $164.00. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $195.99. The firm has a market cap of $52.58 billion, a P/E ratio of 57.48, a PEG ratio of 12.93 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the firm posted $3.68 EPS. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.